213 related articles for article (PubMed ID: 16001982)
61. Age-dependent response of lymphocytes in the induction of the linker histone variant, H1 degrees and histone H4 acetylation after treatment with the histone deacetylase inhibitor, trichostatin A.
Kypreou KP; Sourlingas TG; Sekeri-Pataryas KE
Exp Gerontol; 2004 Apr; 39(4):469-79. PubMed ID: 15050280
[TBL] [Abstract][Full Text] [Related]
62. First-in-human study of the toxicity, pharmacokinetics, and pharmacodynamics of CG200745, a pan-HDAC inhibitor, in patients with refractory solid malignancies.
Kim KP; Park SJ; Kim JE; Hong YS; Lee JL; Bae KS; Cha H; Kwon SK; Ro S; Cho J; Kim TW
Invest New Drugs; 2015 Oct; 33(5):1048-57. PubMed ID: 26076682
[TBL] [Abstract][Full Text] [Related]
63. Combination of valproic acid and ATRA restores RARβ2 expression and induces differentiation in cervical cancer through the PI3K/Akt pathway.
Feng D; Cao Z; Li C; Zhang L; Zhou Y; Ma J; Liu R; Zhou H; Zhao W; Wei H; Ling B
Curr Mol Med; 2012 Mar; 12(3):342-54. PubMed ID: 22229477
[TBL] [Abstract][Full Text] [Related]
64. Chronic sun exposure is associated with distinct histone acetylation changes in human skin.
Ding S; Chen J; Zeng Q; Lu J; Tan L; Guo A; Kang J; Yang S; Xiang Y; Zuo C; Huang J
Br J Dermatol; 2018 Jul; 179(1):110-117. PubMed ID: 29150847
[TBL] [Abstract][Full Text] [Related]
65. Inhibition of MDA-MB-231 breast cancer cell proliferation and tumor growth by apigenin through induction of G2/M arrest and histone H3 acetylation-mediated p21
Tseng TH; Chien MH; Lin WL; Wen YC; Chow JM; Chen CK; Kuo TC; Lee WJ
Environ Toxicol; 2017 Feb; 32(2):434-444. PubMed ID: 26872304
[TBL] [Abstract][Full Text] [Related]
66. Enhancement of in vitro and in vivo tumor cell radiosensitivity by valproic acid.
Camphausen K; Cerna D; Scott T; Sproull M; Burgan WE; Cerra MA; Fine H; Tofilon PJ
Int J Cancer; 2005 Apr; 114(3):380-6. PubMed ID: 15578701
[TBL] [Abstract][Full Text] [Related]
67. A novel imaging flow cytometry method for the detection of histone H4 acetylation in myeloid cells.
Uitrakul S; Hutton C; Veal GJ; Jamieson D
Eur J Clin Invest; 2019 Jul; 49(7):e13115. PubMed ID: 30929275
[TBL] [Abstract][Full Text] [Related]
68. Effects of Histone Deacetylase Inhibitors on the Development of Epilepsy and Psychiatric Comorbidity in WAG/Rij Rats.
Citraro R; Leo A; De Caro C; Nesci V; Gallo Cantafio ME; Amodio N; Mattace Raso G; Lama A; Russo R; Calignano A; Tallarico M; Russo E; De Sarro G
Mol Neurobiol; 2020 Jan; 57(1):408-421. PubMed ID: 31368023
[TBL] [Abstract][Full Text] [Related]
69. Depsipeptide (FR901228) induces histone acetylation and inhibition of histone deacetylase in chronic lymphocytic leukemia cells concurrent with activation of caspase 8-mediated apoptosis and down-regulation of c-FLIP protein.
Aron JL; Parthun MR; Marcucci G; Kitada S; Mone AP; Davis ME; Shen T; Murphy T; Wickham J; Kanakry C; Lucas DM; Reed JC; Grever MR; Byrd JC
Blood; 2003 Jul; 102(2):652-8. PubMed ID: 12649137
[TBL] [Abstract][Full Text] [Related]
70. Hydroxychloroquine, chloroquine, and all-trans retinoic acid regulate growth, survival, and histone acetylation in breast cancer cells.
Rahim R; Strobl JS
Anticancer Drugs; 2009 Sep; 20(8):736-45. PubMed ID: 19584707
[TBL] [Abstract][Full Text] [Related]
71. Lysine deacetylase inhibition attenuates hypertension and is accompanied by acetylation of mineralocorticoid receptor instead of histone acetylation in spontaneously hypertensive rats.
Seok YM; Lee HA; Park KM; Hwangbo MH; Kim IK
Naunyn Schmiedebergs Arch Pharmacol; 2016 Jul; 389(7):799-808. PubMed ID: 27106211
[TBL] [Abstract][Full Text] [Related]
72. CG0006, a novel histone deacetylase inhibitor, induces breast cancer cell death via histone-acetylation and chaperone-disrupting pathways independent of ER status.
Kim HM; Kim CS; Lee JH; Jang SJ; Hwang JJ; Ro S; Hyun YL; Choi J
Breast Cancer Res Treat; 2011 Nov; 130(2):365-75. PubMed ID: 21184271
[TBL] [Abstract][Full Text] [Related]
73. Valproic acid-mediated neuroprotection in retinal ischemia injury via histone deacetylase inhibition and transcriptional activation.
Zhang Z; Qin X; Tong N; Zhao X; Gong Y; Shi Y; Wu X
Exp Eye Res; 2012 Jan; 94(1):98-108. PubMed ID: 22143029
[TBL] [Abstract][Full Text] [Related]
74. Reduction of epileptiform activity by valproic acid in a mouse model of Alzheimer's disease is not long-lasting after treatment discontinuation.
Ziyatdinova S; Viswanathan J; Hiltunen M; Tanila H; Pitkänen A
Epilepsy Res; 2015 May; 112():43-55. PubMed ID: 25847338
[TBL] [Abstract][Full Text] [Related]
75. Manganese chloride induces histone acetylation changes in neuronal cells: Its role in manganese-induced damage.
Guo Z; Zhang Z; Wang Q; Zhang J; Wang L; Zhang Q; Li H; Wu S
Neurotoxicology; 2018 Mar; 65():255-263. PubMed ID: 29155171
[TBL] [Abstract][Full Text] [Related]
76. Histone hyperacetylation occurs on promoters of lytic cycle regulatory genes in Epstein-Barr virus-infected cell lines which are refractory to disruption of latency by histone deacetylase inhibitors.
Countryman JK; Gradoville L; Miller G
J Virol; 2008 May; 82(10):4706-19. PubMed ID: 18337569
[TBL] [Abstract][Full Text] [Related]
77. Valproic acid, a histone deacetylase inhibitor, induces apoptosis in breast cancer stem cells.
Aztopal N; Erkisa M; Erturk E; Ulukaya E; Tokullugil AH; Ari F
Chem Biol Interact; 2018 Jan; 280():51-58. PubMed ID: 29225137
[TBL] [Abstract][Full Text] [Related]
78. Sodium valproate alleviates neurodegeneration in SCA3/MJD via suppressing apoptosis and rescuing the hypoacetylation levels of histone H3 and H4.
Yi J; Zhang L; Tang B; Han W; Zhou Y; Chen Z; Jia D; Jiang H
PLoS One; 2013; 8(1):e54792. PubMed ID: 23382971
[TBL] [Abstract][Full Text] [Related]
79. Histone deacetylase inhibitors valproic acid and depsipeptide sensitize retinoblastoma cells to radiotherapy by increasing H2AX phosphorylation and p53 acetylation-phosphorylation.
Kawano T; Akiyama M; Agawa-Ohta M; Mikami-Terao Y; Iwase S; Yanagisawa T; Ida H; Agata N; Yamada H
Int J Oncol; 2010 Oct; 37(4):787-95. PubMed ID: 20811699
[TBL] [Abstract][Full Text] [Related]
80. Pharmacodynamic response and inhibition of growth of human tumor xenografts by the novel histone deacetylase inhibitor PXD101.
Plumb JA; Finn PW; Williams RJ; Bandara MJ; Romero MR; Watkins CJ; La Thangue NB; Brown R
Mol Cancer Ther; 2003 Aug; 2(8):721-8. PubMed ID: 12939461
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
